Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × ivarmacitinib × Clear all
NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Fudan University

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡